Amicus Therapeutics Biopharmaceutical Company is located in Cranbury, New Jersey. However, in 2008 it grew into a larger firm and expanded from its original set up in Cranbury to a second research site in San Diego. The company was established by major investors including Canaan Partners, Radius Ventures, and New Enterprise Associates.The company`s therapeutical products development relies on the Chaperone Advanced Replacement Therapy (CHART) technology. It has also focused on the development of enzyme replacement therapies (ERTs).
Amicus Therapeutics establishes and develops drugs and medicines that treat lysosomal storage disorders, a rare disease. Unlike other types of treatments which focus on replacing defective enzymes, Amicus Therapeutics uses the small molecule pharmacological chaperones which bind to a victim`s defective proteins and help to restore their functions and activities in the body. In 2014 Amicus Therapeutics Biopharmaceutical Company had the extensive portfolio of small molecule pharmacological chaperones among all other pharmaceutical firms.
In 2014 they developed Migalastat, an advanced pharmacological chaperone for treating Fabry disease. The main aim of the product is to stabilize endogenous mutant alpha-galactosidase. In 2013 Amicus Therapeutics established enzyme replacement therapy for the treatment of a rare disease known as Pombe by use of candidate AT2220. They also developed another candidate, Plicera for the treatment of Gaucher disease.
Amicus Therapeutics Company used to rely on contract manufacturing alone since they had no capability and adequate resources to stand on their own (YahooFinance). It made the company fall into a financial crisis after termination of the collaboration agreement with The Shire in 2009. However, in 2010 Amicus Therapeutics received the grant worth $ 210, 300 from the Alzheimer`s Drug Discovery Foundation. By the end of the year 2015, the Amicus Therapeutics had acquired Scioderm for over $ 947 million in both cash and stock.
The Amicus Therapeutics biopharmaceutical firm has become a leading business and science driven in delivering meaningful benefits and healthcare to their patients globally. The company`s product pipeline and technology platform put in place positions the qualified and experienced staffs at the forefront of developing therapies to meet significant unmet needs for rare and orphan diseases. The company through research is determined to develop drugs for neurodegenerative diseases including Parkinson`s and Alzheimer`s.
More about Amicus Therapeutics on : https://www.indeed.com/q-Amicus-Therapeutics-l-Cranbury,-NJ-jobs.html